Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$1.95 USD
+0.04 (2.09%)
Updated Oct 4, 2024 09:52 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Anebulo Pharmaceuticals, Inc. (ANEB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.33 | $6.00 | $4.00 | 179.06% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Anebulo Pharmaceuticals, Inc. comes to $5.33. The forecasts range from a low of $4.00 to a high of $6.00. The average price target represents an increase of 179.06% from the last closing price of $1.91.
Analyst Price Targets (3 )
Broker Rating
Anebulo Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 4 | 4 | 4 |
Buy | 1 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/1/2024 | The Benchmark Company | Robert Wasserman | Not Available | Moderate Buy |
7/11/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
6/3/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
5/1/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $5.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | NA |
ANEB FAQs
Anebulo Pharmaceuticals, Inc. (ANEB) currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Anebulo Pharmaceuticals, Inc. (ANEB) is $5.33. The current on short-term price targets is based on 1 reports.
The forecasts for Anebulo Pharmaceuticals, Inc. (ANEB) range from a low of $4 to a high of $6. The average price target represents a increase of $179.06 from the last closing price of $1.91.
The current UPSIDE for Anebulo Pharmaceuticals, Inc. (ANEB) is 179.06%
Based on short-term price targets offered by three analysts, the average price target for Anebulo Pharmaceuticals, Inc. comes to $5.33. The forecasts range from a low of $4.00 to a high of $6.00. The average price target represents an increase of 179.06% from the last closing price of $1.91.